Mitochondria Inhibitors
1 drugsAbout Mitochondria
Mitochondria are essential organelles responsible for energy production (ATP) through oxidative phosphorylation, impacting cellular functions like apoptosis and calcium signaling.
Mitochondria are emerging as drug targets, particularly in cardiovascular disease, due to their central role in cellular metabolism; however, there is currently no genetic evidence directly linking them to specific diseases.
Currently, one FDA-approved drug, MYOVIEW, targets mitochondria and is a small molecule; MEDI-PHYSICS is the only company with an approved drug in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Cancer Related Cognitive Decline with only 1 trials.
Top Mitochondria Drugs
MEDI-PHYSICS is the only company with an approved drug targeting mitochondria.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
Mitochondria Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mitochondria, using small molecule modality.
Explore alternative modalities like peptides or gene therapies to differentiate from existing approaches.
Mitochondria Clinical Trials 3 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mitochondria Drug Approval Timeline (1996 - 1996)
The first and only drug, MYOVIEW, was approved in 1996.
The lack of recent approvals indicates potential challenges or a lack of interest in targeting mitochondria, requiring careful evaluation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (8 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 8 clinical trials targeting Mitochondria.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities